CASE REPORT

Thyrotoxicosis Presenting First Time as Hypokalemic Paralysis: A Rare Case Report

Soni Kumar1, Trilok C Guleria2, Pratibha Himral3, Santosh Kumar4, Roshan Lal5

ABSTRACT

Thyrotoxicosis has various clinical manifestations, ranging from its usual features to some rare presentations. Thyrotoxicosis presenting as acute quadriplegia is a very rare phenomenon and is attributed to hypokalemia. Thyrotoxic hypokalemic periodic paralysis is a known but rare manifestation, and a first presentation is relatively unknown in the past. Here, we present a case of middle-aged Asian male in whom thyrotoxicosis presented for the first time as hypokalemic paralysis.

Keywords: Hypokalemia, Hypokalemic periodic paralysis, Quadriplegia, Thyrotoxicosis.

AMEI's Current Trends in Diagnosis & Treatment (2020): 10.5005/jp-journals-10055-0086

INTRODUCTION

Thyrotoxicosis presenting for first time as hypokalemic periodic paralysis (HPP) is a rare entity. It is much more common in patients of Asian descent when compared to the Western population. It may present as rapidly evolving quadriplegia and life-threatening emergency and lead to a diagnostic dilemma for the physicians, and unfamiliarity with the entity can be fatal. Although thyrotoxicosis is more common in women, thyrotoxic periodic paralysis (TPP) is more common in men when compared to women. Here, we report the case of thyrotoxicosis presenting first time as HPP in a middle-aged male farmer who previously had no history of thyroid disease.

CASE DESCRIPTION

A 43-year-old male patient, farmer by occupation, presented to the emergency department with complaints of weakness of all four limbs for 2 days without fever. Next day at 6 AM, the patient tried to get up from sleep to pass urine and realized that he is not able to move his legs. He also could not move side to side in the bed. At this time, the patient could move his arms. This weakness progressed within hours so that the patient could not move his arms as well.

On examination, there was a visible neck swelling involving both lobes of thyroid, moving with deglutition, soft to firm, bilaterally symmetrical, nontender, went unnoticed by the patent as it was there for 8–10 months. On neurological examination, the patient was conscious, oriented with normal higher mental functions and no cranial nerve involvement. Patient had hypotonia with power of 1/5 in all muscle groups at all joints. Deep tendon reflexes were diminished, and superficial reflexes were present. Platers were bilaterally flexors. There were no signs of raised intracranial tension. Cardiovascular examination was normal except for pan-systolic murmur present on the precordium. There were no other signs.

On routine investigations, all were normal except for serum potassium of 1.8 mEq/L. Further investigations were aimed at finding the cause of hypokalemia. The thyroid function test (TFT) showed a depressed thyroid-stimulating hormone—0.03 mU/mL (normal 0.5–4.7), raised free T4—2.8 ng/dL (normal 0.6–2.0), and T3—200 ng/dL (normal 70–190), although clinically there were no features of thyroidosis. His TPO antibody was 74 IU/mL (normal <35). Other causes of hypokalemia, that is gastrointestinal cause, familial hypokalemic paralysis and chronic diuretic use, were excluded after the detailed history and thorough investigations. The above mentioned test results along with clinical signs of a hyperdynamic state confirmed the diagnosis of thyrotoxicosis; with no past history, this was the first presentation of the illness.

The patient was immediately started on intravenous potassium replacement. The patient gradually improved over the next 12 hours and regained full power in 24 hours.

A final diagnosis of thyrotoxic HPP (THPP) was made, and the patient discharged on tablets carbimazole, propranolol, and potassium supplements. He was followed up regularly, and at the end of 2 months TFT was normal. His propranolol was gradually tapered off, and he had no fresh attacks even after 2 months of complete propranolol withdrawal.

DISCUSSION

Hyperthyroidism is a common entity, but its presentation as HPP is most unusual. The first case of nonspecific periodic paralysis was described in 1882. Hypokalemic periodic paralysis association with hyperthyroidism was described by Jakman and Jones.1-2 It is a rare complication of hyperthyroidism, more common in Asian men between second and fourth decades of life. Proximal muscles of
limb (lower > upper) are affected with sparing of higher mental functions, sensory system, and cranial nerves. Patients can present with cardiac arrhythmia, respiratory failure, and thyrotoxicosis crisis.3–5 The exact incidence of THPP is not known in Indian population. In a retrospective study done by Kalitha et al., 52 patients presented as hypokalemic paralysis in 11 years of which only 9 were diagnosed as THPP.5

A differential diagnosis of barium poisoning, familial periodic paralysis, and TPP should be considered. Familial periodic paralysis is differentiated by positive family history, earlier onset, and lack of hyperthyroidism. Further, it is transmitted as autosomal-dominant disorder and more common in white population,7 while THPP is found more in males of Asian/Oriental descent.

The primary defect in TPP is an intracellular sequestration of potassium with normal potassium in the body. Thyroid hormone changes the plasma membrane permeability to potassium by increasing the Na/K-ATPase activity.8,9 In contrast, in familial periodic paralysis, the intracellular shift of potassium is Na/K ATPase independent, and an increase in nonaldosterone mineralocorticoids is present. It responds well to treatment with spironolactone.10

Treatment of hyperthyroidism is mainly done with anti-thyroid drugs and are central to the management of TPP. Urgent correction of potassium levels is the initial treatment. Patients with potassium concentrations above 2.5 mmol/L and mild weakness should be treated with 80 mmol/24 hour of oral potassium. Patients presenting with potassium concentrations below 2.5mmol/L or with symptoms of paralysis should be treated with intravenous potassium at a rate of 20 mmol/hour.11 In the present case, the patient was put on antithyroid drugs to which he responded nicely. Propranolol was added initially to counter the peripheral effects of thyrotoxicosis and improve the muscle strength. Long-term treatment of TPP entails control of hyperthyroidism.12

**Conclusion**

Hyperthyroidism is an uncommon but treatable cause of HPP. This case highlights the importance of entertaining this important possibility in these patients for an early and effective management.

**References**